The Milrinone Lactate Injection, cataloged under National Stock Number 6505-01-694-5728, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Hikma Pharmaceuticals Usa Inc.. Government technical data includes 4 specifications, cited from the U.S. Government catalog. The record lists 3 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 3 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: PG.
| Parameter | Value |
|---|---|
| NSN | 6505-01-694-5728 |
| Primary Part Number | NDC00143-9719-10 |
| Item Name | Milrinone Lactate Injection |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Hikma Pharmaceuticals Usa Inc. |
| Status | ACTIVE |
| Administration | INTRAVENOUS |
| Primary Container Content Quantity | 1.0 MILLILITERS |
| Secondary Container Type | PACKAGE |
| Total Primary Container Quantity | 10 |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | PG |
| Part Number | Manufacturer |
|---|---|
| NDC00143-9719-10 PRIMARY | Hikma Pharmaceuticals Usa Inc. (USA) |
| NDC00338-6010-48 PRIMARY | Baxter Healthcare Corporation (USA) |
| NDC00409-2776-23 | Hospira Worldwide Llc (USA) |
| Reference | Meaning |
|---|---|
| NDC00409-2776-23 | 3/2 Design control — primary reference U.S. Government activity |
| 6505NCM217014 | 5/1 Secondary reference Defense Medical Standardization Board |
| 1592912 | 5/1 Secondary reference U.S. Government activity |
NSN 6505-01-694-5728 is a Milrinone Lactate Injection, manufactured by Hikma Pharmaceuticals Usa Inc., classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-694-5728 has 3 manufacturer part numbers on file: NDC00143-9719-10 (Hikma Pharmaceuticals Usa Inc.), NDC00338-6010-48 (Baxter Healthcare Corporation), NDC00409-2776-23 (Hospira Worldwide Llc).
Key specifications for NDC00143-9719-10: Administration: INTRAVENOUS; Primary Container Content Quantity: 1.0 MILLILITERS; Secondary Container Type: PACKAGE; Special Features: INDICATED FOR THE SHORT-TERM INTRAVENOUS TREATMENT OF PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE; CONTRAINDICATED IN PATIENTS WHO ARE HYPERSENSITIVE TO IT; STORE AT 20 TO 25 C (68 TO 77 F) (SEE USP CONTROLLED ROOM TEMPERATURE); AVOID FREEZING; EXPOSURE OF PHARMACEUTICAL PRODUCTS TO HEAT SHOULD BE MINIMIZED; AVOID EXCESSIVE HEAT; NO PRESERVATIVE IS ADDED; SUPPLIED AS 100 ML (200 MCG/ML) IN 5% DEXTROSE INJECTION SINGLE UNITS; PACKAGE OF 10.. 4 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.